Welcome to our dedicated page for CLSN news (Ticker: CLSN), a resource for investors and traders seeking the latest updates and insights on CLSN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CLSN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CLSN's position in the market.
Celsion Corporation (NASDAQ: CLSN) announced approval from the New Jersey Economic Development Authority to sell $1.5 million in unused net operating losses (NOLs) from 2020 under the NOL program. This will provide Celsion with approximately $1.4 million in cash, augmenting its cash reserves to over $62 million by the end of Q3 2021. The program allows technology companies like Celsion to convert tax losses into cash, reinforcing its commitment to R&D and extending its operating runway through 2024.
Celsion Corporation (NASDAQ: CLSN) has announced that Dr. Khursheed Anwer, Chief Science Officer, will present at the Cytokine-Based Cancer Immunotherapies Summit in Boston from November 30 to December 2, 2021. His presentation will focus on the non-viral gene therapy approach of the company’s GEN-1 immunotherapy, which aims to safely deliver IL-12 for cancer treatment. Dr. Anwer will also participate in two panel discussions regarding cancer immunotherapy.
Positive Phase I results have been reported for GEN-1, currently in Phase II trials.
Celsion Corporation (NASDAQ: CLSN) announced that Dr. Khursheed Anwer, Chief Science Officer, will present virtually at the International Vaccines Congress on October 18, 2021, at 7:30 a.m. ET. His presentation, titled “Immunogenicity of DNA Vaccines based on Multicistronic Vectors and Synthetic DNA Delivery Systems,” can be accessed via the company’s website. Celsion’s PLACCINE platform, which supports next-generation DNA vaccines, is under provisional patent and aims to address various infectious diseases efficiently.
Celsion Corporation (NASDAQ: CLSN) announced that Chief Science Officer Dr. Khursheed Anwer will present at the International Vaccines Congress virtually from October 18-20, 2021. His presentation focuses on the company's proprietary PLACCINE platform for DNA-based vaccines targeting SARS-CoV-2, showcasing the potential for broad-spectrum immunogenicity. Celsion aims to leverage this technology to create effective vaccines against multiple viral mutations.
Celsion GmbH, a subsidiary of Celsion Corporation (CLSN), announces continued research on ThermoDox®, highlighted in a publication in Advanced Drug Delivery Reviews. The article reviews its development from animal studies to Phase III trials for advanced liver cancer. A new Cooperative Research and Development Agreement with the NIH aims to further evaluate ThermoDox® in preclinical studies for rectal and bladder mucosal delivery. The collaboration is expected to enhance understanding of ThermoDox's potential across multiple oncology indications.
Celsion Corporation (NASDAQ: CLSN) announced key management changes to enhance its vaccine development efforts. Carlo Iavarone, Ph.D., joined as Senior Director of Non-Clinical Research, bringing over 15 years of experience in vaccine development. Subeena Sood, Ph.D., was promoted to Senior Manager to oversee assay development for the PLACCINE DNA vaccine. Beth J. Llewellyn joined as Director of Clinical Operations to manage the ongoing Phase II GEN-1 study for advanced ovarian cancer. These strategic hires aim to bolster Celsion's capabilities in RNA vaccine development and immunotherapy.
Celsion Corporation (NASDAQ: CLSN), a clinical-stage biotechnology company, announced its participation in several investment conferences in October 2021. Key events include a presentation at Chardan’s 5th Annual Genetic Medicines Conference on October 5, a virtual presentation at LD Micro Main Event on October 12, and participation in an oncology panel at Alliance Global Partners’ Virtual Healthcare Conference on October 13. Live and archived webcasts will be available online. Celsion focuses on DNA-based immunotherapy, with products like GEN-1 and ThermoDox® in its pipeline.
Celsion Corporation (NASDAQ: CLSN) has expanded its collaboration with Hainan Poly Pharm Co. Ltd. to include the development and manufacturing of clinical and commercial batches for its investigational DNA-based COVID-19 vaccine. The amended agreement allows Poly Pharm to utilize its expertise in chemistry, manufacturing, and controls (CMC) to support Celsion's vaccine, based on its TheraPlas technology. This partnership follows their successful work on Celsion's GEN-1 product, aimed at treating advanced ovarian cancer. Both companies are focused on addressing global health challenges, including the COVID-19 pandemic.
Celsion Corporation (NASDAQ: CLSN) announced promising results from preclinical studies of its PLACCINE DNA vaccine platform against SARS-CoV-2. Immunized BALB/c mice produced antibodies and cytotoxic T-cells targeting the virus's spike antigen, indicating potential protection and the ability to eliminate infected cells. The PLACCINE platform aims for broad-spectrum protection with multiple viral antigens, improved stability at various temperatures, and cost-effective manufacturing. Celsion plans further optimization and will present findings at the International Vaccines Conference in October 2021.
Science 37 has appointed Christine Pellizzari as the new Chief Legal Officer, bringing nearly 30 years of legal experience to enhance the company's mission of accelerating clinical trials. Previously serving at Insmed, Pellizzari's expertise will support Science 37's global expansion and improve access to clinical research for patients and providers. CEO David Coman emphasized her qualifications as instrumental in navigating the evolving decentralized clinical trial landscape.
FAQ
What is the market cap of CLSN (CLSN)?
